190 related articles for article (PubMed ID: 30311653)
1. No survival improvement of contralateral prophylactic mastectomy among women with invasive lobular carcinoma.
Yu TJ; Liu YY; Hu X; Di GH
J Surg Oncol; 2018 Nov; 118(6):928-935. PubMed ID: 30311653
[TBL] [Abstract][Full Text] [Related]
2. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.
Wong SM; Freedman RA; Sagara Y; Aydogan F; Barry WT; Golshan M
Ann Surg; 2017 Mar; 265(3):581-589. PubMed ID: 28169929
[TBL] [Abstract][Full Text] [Related]
3. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.
Pesce C; Liederbach E; Wang C; Lapin B; Winchester DJ; Yao K
Ann Surg Oncol; 2014 Oct; 21(10):3231-9. PubMed ID: 25081341
[TBL] [Abstract][Full Text] [Related]
4. Survival following breast-conserving therapy is equal to that following mastectomy in young women with early-stage invasive lobular carcinoma.
Yu TJ; Liu YY; Hu X; Di GH
Eur J Surg Oncol; 2018 Nov; 44(11):1703-1707. PubMed ID: 30029824
[TBL] [Abstract][Full Text] [Related]
5. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
6. Survival analysis of contralateral prophylactic mastectomy: a question of selection bias.
Kruper L; Kauffmann RM; Smith DD; Nelson RA
Ann Surg Oncol; 2014 Oct; 21(11):3448-56. PubMed ID: 25047478
[TBL] [Abstract][Full Text] [Related]
7. Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I-III unilateral breast cancer in the USA, 1998-2016.
Yang Y; Pan L; Shao Z
Breast Cancer Res Treat; 2021 Dec; 190(3):503-515. PubMed ID: 34554371
[TBL] [Abstract][Full Text] [Related]
8. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
[TBL] [Abstract][Full Text] [Related]
9. Contralateral prophylactic mastectomy and its association with reduced mortality: evidence for selection bias.
Jatoi I; Parsons HM
Breast Cancer Res Treat; 2014 Nov; 148(2):389-96. PubMed ID: 25301088
[TBL] [Abstract][Full Text] [Related]
10. Second primary breast cancer after unilateral mastectomy alone or with contralateral prophylactic mastectomy.
Agarwal S; Pappas L; Matsen CB; Agarwal JP
Cancer Med; 2020 Nov; 9(21):8043-8052. PubMed ID: 32918537
[TBL] [Abstract][Full Text] [Related]
11. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer.
Arrington AK; Jarosek SL; Virnig BA; Habermann EB; Tuttle TM
Ann Surg Oncol; 2009 Oct; 16(10):2697-704. PubMed ID: 19653045
[TBL] [Abstract][Full Text] [Related]
12. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
13. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients.
Bedrosian I; Hu CY; Chang GJ
J Natl Cancer Inst; 2010 Mar; 102(6):401-9. PubMed ID: 20185801
[TBL] [Abstract][Full Text] [Related]
14. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ.
Wong SM; King T; Boileau JF; Barry WT; Golshan M
Ann Surg Oncol; 2017 Sep; 24(9):2509-2517. PubMed ID: 28455673
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Survival Outcomes in Young Patients With Breast Cancer Receiving Contralateral Prophylactic Mastectomy Versus Unilateral Mastectomy.
Huang H; Wei T; Zhang A; Zhang H; Kong L; Li Y; Li F
Clin Breast Cancer; 2023 Oct; 23(7):752-762.e7. PubMed ID: 37586925
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
[TBL] [Abstract][Full Text] [Related]
17. Impact of breast reconstruction on the decision to undergo contralateral prophylactic mastectomy.
Ashfaq A; McGhan LJ; Pockaj BA; Gray RJ; Bagaria SP; McLaughlin SA; Casey WJ; Rebecca AM; Kreymerman P; Wasif N
Ann Surg Oncol; 2014 Sep; 21(9):2934-40. PubMed ID: 24756811
[TBL] [Abstract][Full Text] [Related]
18. Contralateral prophylactic mastectomy in an Asian population: a single institution review.
Sim Y; Tan VK; Ho GH; Wong CY; Madhukumar P; Tan BK; Yong WS; Ng YY; Ong KW
Breast; 2014 Feb; 23(1):56-62. PubMed ID: 24275318
[TBL] [Abstract][Full Text] [Related]
19. Trends of incidence and mortality in metaplastic breast cancer and the effect of contralateral prophylactic mastectomy: A population-based study.
Wu P; Chang H; Wang Q; Shao Q; He D
Asian J Surg; 2024 Jan; 47(1):394-401. PubMed ID: 37739898
[TBL] [Abstract][Full Text] [Related]
20. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ.
Tuttle TM; Jarosek S; Habermann EB; Arrington A; Abraham A; Morris TJ; Virnig BA
J Clin Oncol; 2009 Mar; 27(9):1362-7. PubMed ID: 19224844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
